What is it about?
The m6A RNA demethylase fat mass and obesity-associated protein (FTO) is found to be abnormally elevated in many cancers. In this study, we discovered that vitamin E succinate (VES), a commonly used dietary supplement and vitamin E derivative, functions as an FTO degrader. Reducing FTO levels either through genetic methods or by treatment with VES enhanced the immune response within tumors, increased T cell activity, slowed tumor growth, and made tumors more responsive to immunotherapy.
Featured Image
Photo by Simone van der Koelen on Unsplash
Why is it important?
Our findings on the degradation of FTO and the role of VES provide a foundation for the development of better, more effective FTO degraders. This could help slow tumor growth and reduce resistance to immunotherapy. Furthermore, because VES is a common dietary supplement with a well-established safety profile, it may have the potential as a treatment to aid cancer patients who are resistant to immunotherapy.
Read the Original
This page is a summary of: Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity, Proceedings of the National Academy of Sciences, December 2024, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2407910121.
You can read the full text:
Contributors
The following have contributed to this page
